Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × OTHER_GOV × trametinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 15 NIH 14 INDUSTRY 10 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Neoplasm Metastasis 1

Interventions

pembrolizumab 2 palbociclib 2 durvalumab 2 Metformin 2 Capecitabine 2 tremelimumab 1 trametinib 1 sintilimab 1 olaparib 1 nilotinib 1 nabiximols 1 lenvatinib 1 glasdegib 1 futibatinib 1 enzalutamide 1 dabrafenib 1 citric acid, ispaghula husk, sodium bicarbonate drug combination 1 ceritinib 1 capmatinib 1 capivasertib 1 avelumab 1 atezolizumab 1 anlotinib 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 Zoledronic Acid 1 Vi-siblin 1 Tamoxifen 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡